Fig. 3.

Co-administration of PDMF and nilotinib impairs in vivo tumorigenicity of A549 cells in athymic nude mice. Six week-old BALB/c nude mice were subcutaneously (s.c.) injected with A549 cells (5 × 10⁶ cells/head). Mice were then randomly assigned to seven groups (six mice per group) that were s.c. administered with 40 µl of 0.5% DMSO in PBS (control), 10 µM PDMF (6.4 ng/g murine body weight), 125 µM PDMF (79.7 ng/g body weight), 4 µM nilotinib (4.5 ng/g body weight), 4 μM nilotinib with 10 µM PDMF, 4 µM nilotinib with 125 µM PDMF, or 20 µM nilotinib (22.5 ng/g body weight). 18 days after xenotransplantation, tumor volumes were monitored each three days (a). On day 36, mice were euthanized and final tumor weights were quantified (b). *P < 0.05 indicates significant difference compared with nilotinib only (4 µM)